DBV Technologies S.A. American Depositary Shares
$12.35
-$0.16 (-1.28%)
$12.14Day Range$12.59
Key Statistics
Market Cap
$786.23M
Shares Outstanding
62.8M
Primary Exchange
XNAS
Currency
USD
Type
ADRC
IPO Date
Oct 22, 2014
Round Lot
100
Locale
US
Trading Data
Day Open
$12.59
Day High
$12.59
Day Low
$12.14
Volume
137.6K
VWAP
$12.37
Prev Close
$12.51
Transactions
--
Acc. Volume
--
About DBV Technologies S.A. American Depositary Shares
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 2836170 employees107 AVENUE DE LA REPUBLIQUE, CHATILLON, I0, 9232033(0)155427878IPO Oct 22, 2014US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001613780
- Composite FIGI
- BBG0076D3T39
- Share Class FIGI
- BBG0076D3TV8
- Ticker Root
- DBVT
- SIC Code
- 2836
About DBV Technologies S.A. American Depositary Shares (DBVT) Stock
DBV Technologies S.A. American Depositary Shares (DBVT) closed the 2026-09-18 session at $12.35, down 1.28% versus the previous close (-0.16). The stock opened at $12.59 and traded between $12.14 and $12.59 during that session. Session trading volume was 138K shares. The volume-weighted average price (VWAP) is $12.37.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
DBV Technologies S.A. American Depositary Shares has a market capitalization of $786.2 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. DBVT is listed on the XNAS exchange. The company employs approximately 170 people. DBV Technologies S.A. American Depositary Shares is headquartered in CHATILLON, I0. The recorded listing date is 2014-10-22.
On this page you can find market DBVT stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.